Details

Autor(en) / Beteiligte

• Kim, Min Chong
• Cho, Eun Yoon
• Park, So Yeon
• Lee, Hee Jin
• Lee, Ji Shin
• Kim, Jee Yeon
• Lee, Ho-Chang
• Yoo, Jin Ye
• Kim, Hee Sung
• Kim, Bomi
• Kim, Wan Seop
• Shin, Nari
• Maeng, Young Hee
• Kim, Hun Soo
• Kwon, Sun Young
• Kim, Chungyeul
• Jun, Sun-Young
• Kwon, Gui Young
• Choi, Hye Jeong
• Lee, So Mang
• Choi, Ji Eun
• An, Ae Ri
• Choi, Hyun Joo
• Kim, EunKyung
• Kim, Ahrong
• Kim, Ji-Young
• Shim, Jeong Yun
• Gong, Gyungyub
• Bae, Young Kyung

Titel

A Nationwide Study on HER2-low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols

Ist Teil von

• Cancer research and treatment, 2024-03

Ort / Verlag

Korea (South)

Erscheinungsjahr

2024

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Notable effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2-low advanced breast cancer (BC) has focused pathologists' attention. We studied the incidence and clinicopathologic characteristics of HER2-low BC, and the effects of immunohistochemistry (IHC) associated factors on HER2 IHC results. The Breast Pathology Study Group of the Korean Society of Pathologists conducted a nationwide study using real-world data on HER2 status generated between January 2022 and December 2022. Information on HER2 IHC protocols at each participating institution was also collected. Total 11,416 patients from twenty-five institutions included in this study. Of these patients, 40.7% (range: 6.0%-76.3%) were classified as HER2-zero, 41.7% (range: 10.5%-69.1%) as HER2-low, and 17.5% (range: 6.7%-34.0%) as HER2-positive. HER2-low tumors were associated with positive ER and PR statuses (p<0.001 and p<0.001, respectively). Antigen retrieval times (≥ 36 min vs. < 36 min) and antibody incubation times (≥ 12 min vs. < 12 min) affected on the frequency of HER2 IHC 1+ BC at institutions using the PATHWAY HER2 (4B5) IHC assay and BenchMark XT or Ultra staining instruments. Furthermore, discordant results between core needle biopsy (CNB) and subsequent resection specimen HER2 statuses were observed in 24.1% (787/3259) of the patients. The overall incidence of HER2-low BC in South Korea concurs with those reported in previously published studies. Significant inter-institutional differences in HER2 IHC protocols were observed, and it may have impact on HER2-low status. Thus, we recommend standardizing HER2 IHC conditions to ensure precise patient selection for targeted therapy.